Semaglutide for Cognitive Impairment in Depression
Trial Summary
What is the purpose of this trial?
This trial will test if semaglutide can improve thinking skills in overweight people with depression. Semaglutide is a medication that helps control blood sugar and might also help the brain work better. It is used for weight loss and blood sugar control, and has shown potential benefits for brain function.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you've been treated with oral hypoglycemic agents or insulin in the past 4 weeks.
What data supports the effectiveness of the drug Semaglutide for cognitive impairment in depression?
Is semaglutide safe for humans?
How is the drug semaglutide unique for treating cognitive impairment in depression?
Semaglutide is unique because it is a glucagon-like peptide-1 (GLP-1) analogue that is typically used for diabetes and weight loss, but it may also protect against cognitive decline by enhancing autophagy (the body's way of cleaning out damaged cells) and inhibiting apoptosis (cell death). This mechanism is different from traditional antidepressants, which primarily focus on altering brain chemicals.59101112
Research Team
Rodrigo B. Mansur, MD, PhD
Principal Investigator
University Health Network, Toronto
Eligibility Criteria
This trial is for adults aged 18-60 with major depressive disorder (MDD) who have cognitive issues and are overweight. Participants must perform below average on a specific cognitive test and not be severely depressed, drug-dependent, pregnant, or breastfeeding. They can't have certain mental health conditions or be taking diabetes medications.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive semaglutide or placebo once daily, with dosage adjustments over 16 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Semaglutide
Semaglutide is already approved in European Union, United States, Canada, Japan for the following indications:
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Obesity
- Type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor